Funding sources C.D. was supported by the Stanford Medical Scholars Research Program. The sponsors had no role in the design and conduct of the study; in the collection, analysis and interpretation of data; or in the preparation, review or approval of the manuscript.
Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma
Article first published online: 30 AUG 2013
© 2013 British Association of Dermatologists
British Journal of Dermatology
Volume 169, Issue 3, pages 673–676, September 2013
How to Cite
Danial, C., Lingala, B., Balise, R., Oro, A.E., Reddy, S., Colevas, A. and Chang, A.L.S. (2013), Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma. British Journal of Dermatology, 169: 673–676. doi: 10.1111/bjd.12333
Conflicts of interest A.L.S.C., A.E.O. and A.C. have been investigators of studies sponsored by Genentech, Infinity and Novartis. This study was presented as oral and poster presentations at the Society for Investigative Dermatology Annual Meeting in Raleigh, NC, U.S.A., 9–12 May 2012.
- Issue published online: 30 AUG 2013
- Article first published online: 30 AUG 2013
- Accepted manuscript online: 23 MAR 2013 10:30AM EST
- Manuscript Accepted: 16 MAR 2013
- Stanford Medical Scholars Research Program
Metastatic basal cell carcinoma (BCC) is a rare but life-threatening condition. Prior estimates of overall survival (OS) from time of diagnosis of distant metastasis to death are approximately 8–14 months. However, these estimates are based on analyses of case reports published prior to 1984.
To assess an updated OS in patients with metastatic BCC at a single academic institution.
Using patients seen from 1997 to 2011, a retrospective chart review was performed on biopsy-confirmed cases of distant metastatic BCC at Stanford University School of Medicine. Kaplan–Meier analysis was used to determine OS and progression-free survival (PFS).
Ten consecutive cases of distant metastatic BCC were identified. Median OS was 7·3 years [95% confidence interval (CI) 1·6–∞]; median PFS was 3·4 years (95% CI 1·1–5·2).
Our findings suggest that OS in patients with distant metastatic BCC may be more favourable than previously reported.